Forward-Looking StatementsThe statements in this press release that are not purely historical.

Forward-Looking StatementsThe statements in this press release that are not purely historical, including, without limitation, statements about the progress, timing or the the the research and development of TC-2696 or any of our other product candidates or related regulatory filings or clinical trials, our plans, expectations, future operations, financial position, revenues or costs, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995..

About TargaceptTargacept is a clinical-stage biopharmaceutical company, discovers and develops NNR Therapeutics , a new class of drugs to treat diseases and disorders of the central nervous system. Targacept ‘s product candidates selectively modulate neuronal nicotinic receptors key regulators key regulators of the nervous system to promote therapeutic effects and the negative side effects. Targacept has product candidates in development for Alzheimer’s disease and cognitive deficits in schizophrenia, pain and depression and anxiety disorders, multiple preclinical programs and strategic alliances with AstraZeneca and GlaxoSmithKline. Forward looking statements are available on the website at http://.Just 4 % women in their 40s say she to be new government recommendations on mammograms Ignore.

Drugs that Consumer Affairs arrested doctor for illegal prescriptions of controlled substances, Conn.

Department of Consumer Protection, Conn..

Other Posts From "revitalization":

Related Posts